Shufro Rose & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$41.3M Sell
44,944
-161
-0.4% -$163K 2.81% 7
2025
Q4
$48.5M Buy
45,105
+21
+0% +$20.1K 3.28% 8
2025
Q3
$37.2M Hold
45,084
3.04% 8
2025
Q2
$37.2M Sell
45,084
-30
-0.1% -$23.3K 2.99% 8
2025
Q1
$37.3M Sell
45,114
-600
-1% -$499K 2.94% 8
2024
Q4
$35.3M Sell
45,714
-2,037
-4% -$1.69M 2.73% 9
2024
Q3
$43.2M Hold
47,751
3.51% 4
2024
Q2
$43.2M Buy
47,751
+2,167
+5% +$1.73M 3.51% 4
2024
Q1
$35.5M Sell
45,584
-5
-0% -$3.56K 2.93% 6
2023
Q4
$24.5M Hold
45,589
2.32% 14
2023
Q3
$24.5M Sell
45,589
-5
-0% -$2.58K 2.31% 14
2023
Q2
$21.4M Sell
45,594
-410
-0.9% -$172K 1.95% 17
2023
Q1
$15.8M Sell
46,004
-362
-0.8% -$122K 1.46% 21
2022
Q4
$17M Buy
46,366
+4
+0% +$1.42K 1.43% 23
2022
Q3
$15M Buy
46,362
+107
+0.2% +$33.9K 1.5% 21
2022
Q2
$15M Sell
46,255
-20
-0% -$6K 1.3% 24
2022
Q1
$13.3M Buy
46,275
+102
+0.2% +$26.3K 1.02% 26
2021
Q4
$12.8M Hold
46,173
0.92% 32
2021
Q3
$10.7M Buy
46,173
+20
+0% +$4.94K 0.84% 36
2021
Q2
$10.6M Hold
46,153
0.8% 36
2021
Q1
$8.62M Hold
46,153
0.68% 37
2020
Q4
$7.79M Sell
46,153
-210
-0.5% -$31.4K 0.65% 41
2020
Q3
$6.86M Buy
46,363
+251
+0.5% +$38.8K 0.66% 39
2020
Q2
$7.57M Hold
46,112
0.75% 37
2020
Q1
$6.4M Hold
46,112
0.76% 36
2019
Q4
$6.06M Sell
46,112
-702
-1% -$81.4K 0.55% 43
2019
Q3
$5.24M Sell
46,814
-43
-0.1% -$4.79K 0.52% 47
2019
Q2
$5.19M Buy
46,857
+43
+0.1% +$5.06K 0.51% 49
2019
Q1
$6.08M Sell
46,814
-155
-0.3% -$18.8K 0.61% 47
2018
Q4
$5.43M Sell
46,969
-65
-0.1% -$7.26K 0.6% 45
2018
Q3
$5.05M Hold
47,034
0.47% 60
2018
Q2
$4.01M Hold
47,034
0.38% 68
2018
Q1
$3.64M Sell
47,034
-1,189
-2% -$95.7K 0.36% 69
2017
Q4
$4.07M Sell
48,223
-477
-1% -$40.6K 0.4% 60
2017
Q3
$4.17M Sell
48,700
-455
-0.9% -$37.3K 0.42% 59
2017
Q2
$4.04M Sell
49,155
-300
-0.6% -$24.5K 0.43% 57
2017
Q1
$4.16M Sell
49,455
-900
-2% -$72.1K 0.45% 53
2016
Q4
$3.7M Sell
50,355
-645
-1% -$48K 0.41% 58
2016
Q3
$4.09M Sell
51,000
-337
-0.7% -$27K 0.46% 56
2016
Q2
$4.04M Sell
51,337
-4,418
-8% -$333K 0.45% 58
2016
Q1
$4.01M Buy
55,755
+3,718
+7% +$281K 0.45% 60
2015
Q4
$4.38M Sell
52,037
-663
-1% -$55K 0.5% 55
2015
Q3
$4.41M Sell
52,700
-644
-1% -$54.4K 0.53% 55
2015
Q2
$4.45M Hold
53,344
0.47% 59
2015
Q1
$3.88M Hold
53,344
0.4% 68
2014
Q4
$3.68M Buy
+53,344
New +$3.6M 0.37% 71
2014
Q2
Sell
-4,100
Closed -$241K 265
2014
Q1
$241K Sell
4,100
-2
-0% -$112 0.03% 217
2013
Q4
$209K Buy
+4,102
New +$205K 0.02% 235
2013
Q3
Sell
-4,100
Closed -$201K 258
2013
Q2
$201K Buy
+4,100
New +$223K 0.02% 226

Other funds holding LLY

Shufro Rose & Co's LLY Position: Q1 2026 in Review

Shufro Rose & Co reduced its Eli Lilly (LLY) stake by 0.36% in Q1 2026, selling an estimated $163K and leaving 44,944 shares worth $41.3M. The position accounts for 2.81% of the portfolio, ranked #7.

Shufro Rose & Co first reported a position in LLY in Q2 2013 and has held it in 49 quarters since. The position peaked at $48.5M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Shufro Rose & Co held 44,944 shares of Eli Lilly worth $41.3M as of Q1 2026.
  • Shufro Rose & Co sold 161 Eli Lilly shares in Q1 2026, an estimated $163K.
  • Eli Lilly made up 2.81% of Shufro Rose & Co's portfolio in Q1 2026, its #7 holding.
  • Shufro Rose & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 49 quarters since.
  • Shufro Rose & Co's Eli Lilly position peaked at $48.5M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.